Skip to main content

Advertisement

Table 3 Candidates biomarkers for GDM prediction

From: Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases

Panel A
Protein biomarker Main proposed origin Week of pregnancy Change in GDM Metabolic- and cardiovascular-related properties
RBP4 Liver, adipose, breast 1st–12th/16–20th Higher Pro-inflammatory Glut4 down-regulation and insulin resistance Endothelial dysfunction
SHBG Liver, placenta 1st–13th Lower Polycystic ovary syndrome Insulin resistance
Afamin Liver, placenta 1st–12th Higher Insulin resistance Metabolic syndrome
FABP4 Adipose, placenta 4–6th/23rd–30th Higher Fatty acid uptake, transport, and metabolism
hs-CRP Liver, pancreas, adipose 4–6th/11–14th 16–18th/24–28th Higher Pro-inflammatory of acute response
Adiponectin Adipose, breast 6th–32nd Lower Anti-inflammatory and anti-atherogenesis Insulin-sensitizer
Visfatin Adipose, placenta 11–13th Higher Pro-inflammatory and chemotactic Endothelial dysfunction Acute myocardial infraction
Fetuin-A Liver, placenta, fetal tissues 11–14th Lower Pro-inflammatory Regulation of the insulin receptor Vessel calcification
Omentin-1 Adipose, placenta 12–15th Lower Anti-inflammatory Vasodilatation and endothelial function
IL-6 Adipose, lung 12–15th Higher Pro-inflammatory Atherogenesis and DM
Leptin Adipose, breast 14–20th/24–28th Higher Reduction on insulin action and appetite Pro-oxidant and pro-inflammatory Arterial stiffness
Ficolin-3 Liver, placenta 16th–18th Lower Insulin resistance T2DM development
  1. Some protein (A) and miRs (B) from diverse origins can be early detected in maternal plasma during gestation. Their modified levels have been correlated with later GDM development. Some of them can also provide information about potential metabolic and cardiovascular disorders (https://www.genecards.org/)
Panel B
Genetic biomarker Main proposed origin Week of pregnancy Change in GDM Metabolic- and cardiovascular-related properties
miR-16-5p Placenta 4–6th/16th Higher Pro-inflammatory Regulation of vascular endothelial growth
miR-17-5p Placenta 4–6th/16th Higher Insulin resistance Regulation of angiogenesis Hypertension
miR-20a-5p Placenta 4–6th/16th Higher Regulation of LDL receptor Modulation of aerobic cardiac capacity Coronary artery disease
miR-21-3p Placenta 7th–23rd/30–36th Higher Pro-inflammatory Insulin resistance
miR-29a Placenta 16th Lower Repression of insulin-signaling Regulation of Glut4 Control of fatty acid/glucose metabolism
miR-132 Placenta 16th Lower Insulin secretion Enhancement of glucose homeostasis
miR-222 Placenta 16th Lower Insulin resistance Downregulation of Glut4 Hypercholesterolemia
miR-19a/b-3p Placenta 16th Higher Pro-inflammatory Insulin resistance Vascular injury
  1. Some protein (A) and miRs (B) from diverse origins can be early detected in maternal plasma during gestation. Their modified levels have been correlated with later GDM development. Some of them can also provide information about potential metabolic and cardiovascular disorders (https://www.genecards.org/)